U.S. Markets close in 5 hrs 37 mins
  • S&P 500

    4,690.82
    -10.39 (-0.22%)
     
  • Dow 30

    35,689.15
    -65.60 (-0.18%)
     
  • Nasdaq

    15,719.02
    -67.97 (-0.43%)
     
  • Russell 2000

    2,258.02
    -13.69 (-0.60%)
     
  • Crude Oil

    71.82
    -0.54 (-0.75%)
     
  • Gold

    1,775.60
    -9.90 (-0.55%)
     
  • Silver

    21.94
    -0.49 (-2.19%)
     
  • EUR/USD

    1.1296
    -0.0049 (-0.4292%)
     
  • 10-Yr Bond

    1.4870
    -0.0220 (-1.46%)
     
  • Vix

    20.15
    +0.25 (+1.26%)
     
  • GBP/USD

    1.3206
    -0.0001 (-0.0040%)
     
  • USD/JPY

    113.5250
    -0.2120 (-0.1864%)
     
  • BTC-USD

    48,500.12
    -2,476.12 (-4.86%)
     
  • CMC Crypto 200

    1,266.24
    -39.71 (-3.04%)
     
  • FTSE 100

    7,321.80
    -15.25 (-0.21%)
     
  • Nikkei 225

    28,725.47
    -135.15 (-0.47%)
     

GlycoMimetics to Report First Quarter Financial Results on May 3, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET.

The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 9891637. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect.

A webcast replay will be available via the "Investors" tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 9891637.

About GlycoMimetics, Inc.

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005438/en/

Contacts

Investor Contact:
Shari Annes
Phone: 650-888-0902
Email: sannes@annesassociates.com

Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email: jamielacey@presscommpr.com